258 related articles for article (PubMed ID: 21812863)
1. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
3. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
5. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
[TBL] [Abstract][Full Text] [Related]
6. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
Mauser-Bunschoten EP; Kleine Budde I; Lopaciuk S; Koopman MM; Van Der Meer FJ; Novàkovà IR; Ypma P; Van Der Linden PW; Windyga J; Strengers PF
Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
[TBL] [Abstract][Full Text] [Related]
7. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
[TBL] [Abstract][Full Text] [Related]
9. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
Uprichard J; Adamidou D; Goddard NJ; Mann HA; Yee TT
Haemophilia; 2012 Jan; 18(1):46-9. PubMed ID: 21545378
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
Quon DV; Logan L
Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
[TBL] [Abstract][Full Text] [Related]
12. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
[TBL] [Abstract][Full Text] [Related]
15. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
16. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
[TBL] [Abstract][Full Text] [Related]
18. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
Hoots WK; Leissinger C; Stabler S; Schwartz BA; White G; Dasani H; Massion C; Negrier C; Schindel F; Schulman S
Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of OCTANINE F in children with haemophilia B.
Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]